Mesoblast (MESO) vs Xencor (XNCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Xencor (XNCR) has outperformed Mesoblast (MESO) over the past year, gaining 101.7% versus a loss of 22.9%. Over five years, MESO leads with a +22.7% price change compared with -36.9% for XNCR. Mesoblast is the larger company by market cap ($1.81 billion vs $1.80 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MESO | XNCR |
|---|---|---|
| Share price | $13.94 | $24.26 |
| Market cap | $1.81B | $1.80B |
| 1-day change | +2.42% | -0.41% |
| YTD return | -22.73% | +58.46% |
| 1-year return | -22.94% | +101.66% |
| 5-year return | +22.71% | -36.94% |
| Forward P/E | 30.64 | — |
| EPS (TTM) | $-0.44 | $-2.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $21.50 | $30.61 |
| 52-week low | $13.05 | $10.38 |
| Distance from 52-week high | -35.16% | -20.74% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +165.42% | +29.51% |
| Average volume | 236.60K | 1.30M |
| Shares outstanding | 129.85M | 74.35M |
| Employees | 108 | 260 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XNCR has outperformed MESO by 124.6 percentage points over the past year.
About Mesoblast
MESO stock →Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Healthcare · Biotechnology · 108 employees
About Xencor
XNCR stock →Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Healthcare · Biotechnology · 260 employees
MESO vs XNCR FAQ
Which is bigger, Mesoblast or Xencor?
Mesoblast (MESO) is larger, with a market capitalization of $1.81B compared with $1.80B for Xencor (XNCR).
Which stock has performed better over the past year, MESO or XNCR?
XNCR returned +101.66% over the past 12 months, compared with -22.94% for MESO (price return, excluding dividends). Past performance does not predict future results.
Are Mesoblast and Xencor in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.